214 related articles for article (PubMed ID: 12957861)
1. CD36: a critical anti-angiogenic receptor.
Simantov R; Silverstein RL
Front Biosci; 2003 Sep; 8():s874-82. PubMed ID: 12957861
[TBL] [Abstract][Full Text] [Related]
2. CD36-TSP-HRGP interactions in the regulation of angiogenesis.
Silverstein RL; Febbraio M
Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36.
Klenotic PA; Page RC; Li W; Amick J; Misra S; Silverstein RL
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1655-62. PubMed ID: 23640500
[TBL] [Abstract][Full Text] [Related]
4. Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.
Hale JS; Li M; Sinyuk M; Jahnen-Dechent W; Lathia JD; Silverstein RL
PLoS One; 2012; 7(7):e40033. PubMed ID: 22808089
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.
Chu LY; Ramakrishnan DP; Silverstein RL
Blood; 2013 Sep; 122(10):1822-32. PubMed ID: 23896411
[TBL] [Abstract][Full Text] [Related]
6. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.
Simantov R; Febbraio M; Silverstein RL
Matrix Biol; 2005 Feb; 24(1):27-34. PubMed ID: 15748999
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36.
Yang M; Li K; Ng MH; Yuen PM; Fok TF; Li CK; Hogg PJ; Chong BH
Thromb Res; 2003 Jan; 109(1):47-54. PubMed ID: 12679131
[TBL] [Abstract][Full Text] [Related]
8. Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling.
Anderson CR; Hastings NE; Blackman BR; Price RJ
Am J Pathol; 2008 Oct; 173(4):1220-8. PubMed ID: 18772338
[TBL] [Abstract][Full Text] [Related]
9. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
Koch M; Hussein F; Woeste A; Gründker C; Frontzek K; Emons G; Hawighorst T
Breast Cancer Res Treat; 2011 Jul; 128(2):337-46. PubMed ID: 20714802
[TBL] [Abstract][Full Text] [Related]
10. Localization of thrombospondin-1 and its receptor CD36 in the ovary of the ostrich (Struthio camelus).
Rodler D; Sinowatz F
Anat Histol Embryol; 2018 Apr; 47(2):124-132. PubMed ID: 29205453
[TBL] [Abstract][Full Text] [Related]
11. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36.
Yehualaeshet T; O'Connor R; Green-Johnson J; Mai S; Silverstein R; Murphy-Ullrich JE; Khalil N
Am J Pathol; 1999 Sep; 155(3):841-51. PubMed ID: 10487979
[TBL] [Abstract][Full Text] [Related]
12. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.
Simantov R; Febbraio M; Crombie R; Asch AS; Nachman RL; Silverstein RL
J Clin Invest; 2001 Jan; 107(1):45-52. PubMed ID: 11134179
[TBL] [Abstract][Full Text] [Related]
13. Association of thrombospondin-1 with the actin cytoskeleton of human thrombin-activated platelets through an alphaIIbbeta3- or CD36-independent mechanism.
Saumet A; de Jesus N; Legrand C; Dubernard V
Biochem J; 2002 May; 363(Pt 3):473-82. PubMed ID: 11964147
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
[TBL] [Abstract][Full Text] [Related]
15. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts.
Zhao XM; Hu Y; Miller GG; Mitchell RN; Libby P
Circulation; 2001 Jan; 103(4):525-31. PubMed ID: 11157717
[TBL] [Abstract][Full Text] [Related]
16. Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum.
Petrik JJ; Gentry PA; Feige JJ; LaMarre J
Biol Reprod; 2002 Nov; 67(5):1522-31. PubMed ID: 12390884
[TBL] [Abstract][Full Text] [Related]
17. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.
Dawson DW; Pearce SF; Zhong R; Silverstein RL; Frazier WA; Bouck NP
J Cell Biol; 1997 Aug; 138(3):707-17. PubMed ID: 9245797
[TBL] [Abstract][Full Text] [Related]
18. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.
Kazerounian S; Duquette M; Reyes MA; Lawler JT; Song K; Perruzzi C; Primo L; Khosravi-Far R; Bussolino F; Rabinovitz I; Lawler J
Blood; 2011 Apr; 117(17):4658-66. PubMed ID: 21378271
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin-1 expression is increased during follicular atresia in the primate ovary.
Thomas FH; Wilson H; Silvestri A; Fraser HM
Endocrinology; 2008 Jan; 149(1):185-92. PubMed ID: 17884943
[TBL] [Abstract][Full Text] [Related]
20. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
